Cellectis S.A.. (4/12/17). "Press Release: Cellectis S.A. to Explore Possible Initial Public Offering of Calyxt, Inc.".

	Organisation	Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
	Group	Cellectis (Group)
	Organisation 2	Calyxt Inc. (Nasdaq Global Market: CLXT)
	Group	Cellectis (Group)
	Product	TALEN® technology (Transcription Activator-Like Effector Nuclease)
	Product 2	plant biotechnology
	Person	Moore, Jennifer (Cellectis 201511 VP Communications)
	Person 2	Harnest, Simon (Metagenomi 202107– Chief Investment Officer + SVP Strategy before Cellectis + Trout Group)

Cellectis (Alternext: ALCLS; Nasdaq: CLLS) today announces that it is exploring the possibility of an initial public offering (IPO) of a minority interest in its plant sciences business, Calyxt, Inc. No decisions have been taken at this point on the structure or timing of any IPO, and no assurance can be given that an IPO will be pursued.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

For further information, please contact:

Media contacts:
Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241,
ckasunich@kcsa.com

IR contact:
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,
simon.harnest@cellectis.com

Record changed: 2023-06-05